The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
/in International Publications, Malignant Melanoma, Newcastle Disease VirusRegional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum
/in Colorectal Cancer, Hyperthermia, International PublicationsIdentification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy
/in Dendritic Cells, International PublicationsTowards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines
/in Dendritic Cells, International PublicationsPersonalized dendritic cell-based tumor immunotherapy
/in Dendritic Cells, International PublicationsDendritic cell vaccines for brain tumors
/in Dendritic Cells, Glioblastoma, International PublicationsClinical applications of a peptide-based vaccine for glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsMonitoring immune responses after glioma vaccine immunotherapy
/in Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer